IDEAYA Biosciences/$IDYA
1D1W1MYTD1Y5YMAX
Capital at risk
About IDEAYA Biosciences
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
- Ticker
- $IDYA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 145
- Headquarters
- South San Francisco, United States
- Website
- www.ideayabio.com
IDYA Metrics
BasicAdvanced
$3.5B
-
-$1.96
-0.08
-
Price and volume
Market cap
$3.5B
Beta
-0.08
52-week high
$42.68
52-week low
$25.54
Average daily volume
823K
Financial strength
Current ratio
10.451
Quick ratio
10.213
Long term debt to equity
0.023
Total debt to equity
0.024
Profitability
EBITDA (TTM)
-214.195
Gross margin (TTM)
-59.75%
Net profit margin (TTM)
-74.75%
Operating margin (TTM)
-92.66%
Revenue per employee (TTM)
$1,610,000
Management effectiveness
Return on assets (TTM)
-11.54%
Return on equity (TTM)
-16.22%
Valuation
Price to revenue (TTM)
14.021
Price to book
2.95
Price to tangible book (TTM)
2.95
Price to free cash flow (TTM)
-28.829
Free cash flow yield (TTM)
-3.47%
Free cash flow per share (TTM)
-1.273
Growth
Revenue change (TTM)
3,244.67%
Earnings per share change (TTM)
-48.35%
3-year revenue growth (CAGR)
73.09%
3-year earnings per share growth (CAGR)
8.41%
What the Analysts think about IDYA
Analyst ratings (Buy, Hold, Sell) for IDEAYA Biosciences stock.
Analyst projections of the future price of IDEAYA Biosciences stock.
Bulls say / Bears say
Darovasertib plus crizotinib cut the risk of progression by 58% in the registrational OptimUM-02 trial, with median progression-free survival of 6.9 months versus 3.1 months for investigator-choice therapy. IDEAYA is using the FDA’s Real-Time Oncology Review pathway and expects to complete the NDA filing in the second half of 2026. (IDEAYA Biosciences, IDEAYA Biosciences)
Darovasertib could address more than metastatic disease. IDEAYA and Servier have begun the global Phase 3 OptimUM-11 adjuvant trial, where the company says there are currently no approved adjuvant options for primary uveal melanoma; the partners are sharing development costs. (IDEAYA Biosciences, IDEAYA Biosciences)
The company has substantial funding to pursue several programmes: cash, cash equivalents and marketable securities stood at about $1.24 billion at 30 June, with management maintaining runway guidance into 2030. IDE849 also gained FDA agreement on a Phase 3 design in extensive-stage small-cell lung cancer, while Roche and Genentech collaborations broaden the potential MTAP-deleted cancer opportunity. (IDEAYA Biosciences, IDEAYA Biosciences)
The strongest OptimUM-02 evidence is progression-free survival, not overall survival: OS data were still immature at the January 2026 cut-off and the next planned interim analysis is not expected until mid-2027. Regulatory review is also unfinished, so the positive PFS result does not yet guarantee approval or a durable survival benefit. (IDEAYA Biosciences, Longbridge)
Execution in the uveal-melanoma pipeline has already shown friction. IDEAYA said stricter eligibility criteria caused higher screening failures and delayed OptimUM-10 enrolment, while the new adjuvant study may compete for patients, forcing a reassessment of the programme. (IDEAYA Biosciences, Equibles)
IDE849 remains an early-stage bet despite the FDA meeting: its global study is still a Phase 1 trial, and a Phase 3 start does not establish efficacy, tolerability or approval. IDEAYA itself warns that the FDA’s feedback is preliminary and non-binding and that later trials may fail to confirm the early results. (IDEAYA Biosciences, IDEAYA Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
IDYA Financial Performance
Revenues and expenses
IDYA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing IDYA
AllUSDEURGBP
Fund name | Fund size | $IDYA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.33% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.33% |
iShares Healthcare Innovation£DRDR | £1B | 0.33% |
iShares Ageing Population€AGED | €822M | 0.28% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.23% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.